ATE275970T1 - Impfstoffzusammensetzungen - Google Patents

Impfstoffzusammensetzungen

Info

Publication number
ATE275970T1
ATE275970T1 AT94928455T AT94928455T ATE275970T1 AT E275970 T1 ATE275970 T1 AT E275970T1 AT 94928455 T AT94928455 T AT 94928455T AT 94928455 T AT94928455 T AT 94928455T AT E275970 T1 ATE275970 T1 AT E275970T1
Authority
AT
Austria
Prior art keywords
double mutant
antigen
substituted
manufacture
amino acid
Prior art date
Application number
AT94928455T
Other languages
English (en)
Inventor
Mark Roberts
Original Assignee
Celltech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26303633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275970(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB939320454A external-priority patent/GB9320454D0/en
Priority claimed from GB939324743A external-priority patent/GB9324743D0/en
Application filed by Celltech Pharmaceuticals Ltd filed Critical Celltech Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE275970T1 publication Critical patent/ATE275970T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94928455T 1993-10-05 1994-10-04 Impfstoffzusammensetzungen ATE275970T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939320454A GB9320454D0 (en) 1993-10-05 1993-10-05 Vaccine compositions
GB939324743A GB9324743D0 (en) 1993-12-02 1993-12-02 Adjuvant compositions
PCT/GB1994/002152 WO1995009649A1 (en) 1993-10-05 1994-10-04 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE275970T1 true ATE275970T1 (de) 2004-10-15

Family

ID=26303633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928455T ATE275970T1 (de) 1993-10-05 1994-10-04 Impfstoffzusammensetzungen

Country Status (7)

Country Link
US (2) US7169399B2 (de)
EP (1) EP0725653B2 (de)
AT (1) ATE275970T1 (de)
AU (1) AU7788194A (de)
DE (1) DE69434000T3 (de)
DK (1) DK0725653T3 (de)
WO (1) WO1995009649A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
ATE275970T1 (de) 1993-10-05 2004-10-15 Celltech Pharmaceuticals Ltd Impfstoffzusammensetzungen
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
EP1790358A1 (de) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
NZ602958A (en) 2010-03-30 2014-07-25 Pfenex Inc High level expression of recombinant toxin proteins
IN2014CN04700A (de) * 2011-12-21 2015-09-18 Bionet Asia Co Ltd
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2016011155A1 (en) * 2014-07-15 2016-01-21 Kapre Subhash V Genetically detoxified pertussis that maintains intrinsic adjuvant activity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
JPH03500606A (ja) 1988-05-05 1991-02-14 アプライド　マイクロバイオロジー，インコーポレイテッド プロテアーゼ欠損グラム陽性菌類及び組換え体産生用宿主有機体としての用途
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
DK0396964T3 (da) * 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
US5601826A (en) * 1989-06-30 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
DK0425082T3 (da) 1989-09-04 1995-07-03 Evans Medical Ltd Vacciner
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
IT1248735B (it) 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE275970T1 (de) 1993-10-05 2004-10-15 Celltech Pharmaceuticals Ltd Impfstoffzusammensetzungen
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans

Also Published As

Publication number Publication date
DE69434000T3 (de) 2008-11-06
DE69434000T2 (de) 2005-01-27
US20100255033A1 (en) 2010-10-07
DE69434000D1 (de) 2004-10-21
DK0725653T3 (da) 2004-10-11
AU7788194A (en) 1995-05-01
US20010018056A1 (en) 2001-08-30
EP0725653B2 (de) 2008-04-02
EP0725653A1 (de) 1996-08-14
WO1995009649A1 (en) 1995-04-13
EP0725653B1 (de) 2004-09-15
US7169399B2 (en) 2007-01-30

Similar Documents

Publication Publication Date Title
NZ291262A (en) E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants
ATE275970T1 (de) Impfstoffzusammensetzungen
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
GB9419979D0 (en) Vaccine compositions
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
IS3753A7 (is) Endurbætt aðferð og samsetning bóluefnis
HK1121382A1 (en) Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines
GB9209118D0 (en) Vaccine compositions
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DE69317435T2 (de) Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden
FR2693655B1 (fr) Vaccin antirabique avirulent.
GB9500788D0 (en) Vaccine compositions
HK1025220A1 (en) Novel saponin compositions and uses thereof
EA200300557A1 (ru) Комбинированные композиции адъювантов
DE69128095D1 (de) Azelluläre impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties